Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)
Completed
- Conditions
- Hepatitis B, Chronic
- Registration Number
- NCT01155427
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to support the clinical value of entecavir by assessing the relationship between viral load and histological improvement.
- Detailed Description
Systematic review of prospective clinical trials
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patients with CHB diagnosis and no co-infection with Hep A, Hep C, Hep D, or HIV
- Age 16 years or older
- No post-transplant patients
- RCT, non-randomized trials, prospective cohort studies, prospectively analyses case series published since 2003
- At least one arm of trial must include monotherapy with entecavir, lamivudine, tenofovir, adefovir, or telbivudine
- Study arms must include at least 10 patients
- Follow-up of at least 48 weeks
- Published results available in English language
Read More
Exclusion Criteria
- N/A
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Viral load Histological improvement
- Secondary Outcome Measures
Name Time Method